Evolutionary Genomics Inc FNAM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.45
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.45
- Bid/Ask
- $0.06 / $1.00
- Market Cap
- $5,324.19
- Volume/Avg
- 15,832 / 15,832
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 4
- Website
- https://www.evolgen.com
Valuation
|
Metric
|
FNAM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FNAM
|
|---|---|
Quick Ratio | 3.68 |
Current Ratio | 3.92 |
Interest Coverage | — |
Quick Ratio
FNAM
Profitability
|
Metric
|
FNAM
|
|---|---|
Return on Assets (Normalized) | −59.78% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
FNAM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Vxmmkwcyw | Dpgm | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nzrhwtwl | Jcrwkv | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kqlmdsyx | Qrdsfx | $118.7 Bil | |||
| Moderna Inc
MRNA
| Qbdwzlkp | Mnzcc | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wzxqjlzqw | Vzzrmhj | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Shrrylcl | Jpth | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Jprspygj | Tzmv | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xknnrdcy | Zwbhyk | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Qbqgjdhq | Vqbp | $15.0 Bil | |||
| Incyte Corp
INCY
| Pkvyllnc | Yzhxpx | $13.5 Bil |